Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer

AACHEN, Germany, Nov. 22, 2022 /PRNewswire/ -- Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She worked closely with Research & Development and the Licensing & Acquisitions teams to strengthen the company's pipeline. Janneke van der Kamp has vast expertise in launching and growing key brands across several disease areas. She is a studied chemist and holds an MBA from INSEAD.

As CCO of Grünenthal, Janneke van der Kamp will be responsible for the entire Global Commercial Organisation and serve as a member of the Corporate Executive Board. Her focus will be to continue to grow the company's key brands, prepare for the launch of Grünenthal's pipeline assets and maximise the portfolio of established medicines.

"Grünenthal is a company with an excellent commercial performance and a compelling vision of a World Free of Pain," says Janneke van der Kamp. "I am looking forward to meeting the teams around the world and together drive the growth of Grünenthal's portfolio and prepare to bring new medicines to patients."

Janneke van der Kamp succeeds Grünenthal's current CCO, Mark Fladrich, who will retire from Grünenthal effective 28 February 2023. Over the past five years, Mark Fladrich has transformed Grünenthal's commercial organisation. Key achievements included attracting and developing talents and the creation of a strong, patient and customer-oriented culture to support Grünenthal's vision of a World Free of Pain. Under his leadership, the European and Latin American businesses have been transformed, and Grünenthal has successfully entered the US market. The Grünenthal product portfolio has consistently grown which has contributed to the company's strong profit growth over the last five years.

"With Janneke, we gain an exceptional leader with an excellent track record of developing high-performing, diverse teams and launching industry-leading brands. We are excited to welcome her to the team," says Gabriel Baertschi, Chief Executive Officer Grünenthal.

"I want to thank Mark for everything he has done for Grünenthal, our portfolio and our people. His leadership, counsel and character will be missed. I wish him and his family all the best for the future."  

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.

Picture is available at AP Images (http://www.apimages.com)

More information: www.grunenthal.com

Click here for our Grünenthal Report 2021/2022

Follow us on: 
LinkedIn: Grunenthal Group
Instagram: grunenthal

For further information, please contact